Why I Love GlaxoSmithKline plc

GlaxoSmithKline plc (LON: GSK) has suffered one or two setbacks lately, but that only reminds Harvey Jones how much he loves it.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There is something to love and hate in most stocks, although GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) is more lovable than most. Here are five things I really like about it today.

Glaxo is big enough to fail

The late-stage failure of Glaxo’s $10 billion-a-year megablockbuster heart drug Darapaldib was a blow, even if it may still have niche uses. It isn’t the only recent big failure on Glaxo’s, either — cancer vaccine MAGE-A3 also suffered a late-stage flop. This even prompted broker Panmure Gordon to cut its rating from ‘buy’ to ‘hold’. But with four R&D approvals out of six this year, Glaxo still has plenty to offer, and should avoid following AstraZeneca over the dreaded patent cliff.

It is also big enough to survive China

The China bribery scandal sparked a 61% drop in sales in the country, as doctors refuse to see Glaxo sales staff. But Glaxo’s bottom line can withstand that, too, given that Chinese revenues account for less than 5% of its global total. That’s the value of global diversification. Better still, rumours suggest the China crisis is easing. Glaxo should brace itself for a meaty fine, but is thought unlikely to be slung out of the country. In China, anything can happen, of course. But one thing is certain: Glaxo will survive.

It’s a great share to buy and forget

Last month, Barclays lowered Glaxo’s target price from 1555p to 1545p and retained an equal-weight rating. JP Morgan cut its target price from 1900p to 1750p and stuck it in neutral. With the share price currently 1611p, neither expect much growth. But frankly, who cares? Glaxo is the ultimate buy-and-forget stock in my portfolio. A stock I plan to retire on. Given time, the growth will come. Until then, the dividends will keep rolling in.

Management looks after shareholders

Glaxo generates loads of cash, with net cash flow of £2.3 billion in the third quarter, and is using it to reward loyal shareholders. It has made £1 billion of share buybacks so far this year, and management is targeting up to £2 billion. The Q3 dividend was lifted 6% to 19p. Today, Glaxo yields 4.6%, covered 1.5 times, comfortably above the FTSE 100 average of 3.5%. Loyalty pays.

This company doesn’t rest

Despite piling up all that cash, Glaxo is still focused on reducing costs and improving processes in a bid to save £1 billion a year by 2016. It has also improved its strategic focus and boosted growth prospects by selling Lucozade and Ribena to Suntory for a fizzy £1.35 billion. Its acquisition of US biotechnology partner Human Genome Sciences will help its push to develop new products. Glaxo has struggled lately but, in the longer run, there is still plenty to love.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Harvey owns shares in GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »